Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arpita Aggarwal

Internal Medicine Glen Allen, VA Medical Doctor

NPI 1306939459 CMS profile 769811

5360 Twin Hickory Rd, Glen Allen, VA 23059

Open in the dashboard

General payments

$7,668

461 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arpita Aggarwal of Glen Allen, VA is reported in the CMS Open Payments database as having received $7,668 across 461 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,367 70
2024 General $1,139 68
2023 General $1,141 61
2022 General $782 49
2021 General $888 59
2020 General $1,512 93
2019 General $840 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arpita Aggarwal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Arpita Aggarwal were reported at $1,367. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Arpita Aggarwal Internal Medicine median Middle half National median
2019 $840 $159 $48–$570 $163
2020 $1,512 $119 $33–$402 $114
2021 $888 $135 $37–$521 $132
2022 $782 $141 $42–$496 $149
2023 $1,141 $149 $45–$519 $160
2024 $1,139 $154 $47–$537 $164
2025 $1,367 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,459 98 payments
  2. Novo Nordisk Inc $932 61 payments
  3. Amgen Inc. $702 48 payments
  4. AstraZeneca Pharmaceuticals LP $695 36 payments
  5. Pfizer Inc. $580 32 payments
  6. Lilly USA, LLC $477 27 payments
  7. Merck Sharp & Dohme Corporation $355 26 payments
  8. Amarin Pharma Inc. $271 15 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $217 13 payments
  10. GlaxoSmithKline, LLC. $186 7 payments
  11. Other $1,794 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,662 460 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $761 52 payments
  2. Ozempic $725 48 payments
  3. RYBELSUS $572 38 payments
  4. QULIPTA $421 30 payments
  5. VRAYLAR $407 26 payments
  6. FARXIGA $369 18 payments
  7. EVENITY $336 21 payments
  8. NURTEC ODT $286 15 payments
  9. Prolia $280 18 payments
  10. AIRSUPRA $243 7 payments
  11. Other $6,703 413 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

4,540

Median for Internal Medicine: 777

Drug cost

$442,532

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 96 $128,013
Januvia Sitagliptin Phosphate Brand 42 $49,467
Eliquis Apixaban Brand 39 $38,640
Repatha Sureclick Evolocumab Brand 34 $35,775
Xarelto Rivaroxaban Brand 30 $33,659
Mounjaro Tirzepatide Brand 23 $27,382
Trulicity Dulaglutide Brand 24 $24,232
Ozempic Semaglutide Brand 16 $23,737
Farxiga Dapagliflozin Propanediol Brand 11 $14,659
Breo Ellipta Fluticasone/Vilanterol Brand 18 $10,503

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 101 billing codes

Paid by Medicare

$141,730

Of which drugs: $28,830

Medicare patients

246

Average age 74

Services billed

4,983

177 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 52%
Ischemic heart disease 36%
Chronic kidney disease 25%
Depression 25%
Diabetes 23%
Osteoporosis 23%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 21 22 $6,060
Vaccine for influenza for injection into muscle 90662 Office 38 38 $3,109

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $125
$125 — —
VRAYLAR
  • AbbVie, Inc. $122
$122 — —
QULIPTA
  • AbbVie, Inc. $121
$121 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $25
  • Lilly USA, LLC $22
$47 96 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record